StreetInsider.com News Articles

Form DEFA14A Vaxart, Inc.

Mon, 01 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260601/26584977.html

Form DEFA14A Vaxart, Inc.

Mon, 01 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260601/26584977.html

Form ARS Vaxart, Inc. For: Dec 31

Mon, 01 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260601/26584852.html

Form ARS Vaxart, Inc. For: Dec 31

Mon, 01 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260601/26584852.html

Form DEFA14A Vaxart, Inc.

Mon, 01 Jun 2026 08:44:00 -0400

si-local-file:///var/storage/secattach/20260601/26580040.html

Form DEFA14A Vaxart, Inc.

Mon, 01 Jun 2026 08:44:00 -0400

si-local-file:///var/storage/secattach/20260601/26580040.html

Form DEFA14A Vaxart, Inc.

Mon, 01 Jun 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260601/26579950.html

Form DEFA14A Vaxart, Inc.

Mon, 01 Jun 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260601/26579950.html

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Mon, 01 Jun 2026 08:18:00 -0400

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead

Highlights Significant Risk of Replacing Vaxart’s Highly Qualified Directors with Candidates Who Have No Relevant Expertise

Urges Shareholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY

Visit Vote.Vaxart.com for Additional Information and Voting Resources

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Mon, 01 Jun 2026 08:18:00 -0400

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead

Highlights Significant Risk of Replacing Vaxart’s Highly Qualified Directors with Candidates Who Have No Relevant Expertise

Urges Shareholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY

Visit Vote.Vaxart.com for Additional Information and Voting Resources

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Mon, 01 Jun 2026 08:18:00 -0400

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead

Highlights Significant Risk of Replacing Vaxart’s Highly Qualified Directors with Candidates Who Have No Relevant Expertise

Urges Shareholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY

Visit Vote.Vaxart.com for Additional Information and Voting Resources

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Mon, 01 Jun 2026 08:18:00 -0400

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead

Highlights Significant Risk of Replacing Vaxart’s Highly Qualified Directors with Candidates Who Have No Relevant Expertise

Urges Shareholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY

Visit Vote.Vaxart.com for Additional Information and Voting Resources

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Mon, 01 Jun 2026 08:18:00 -0400

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead

Highlights Significant Risk of Replacing Vaxart’s Highly Qualified Directors with Candidates Who Have No Relevant Expertise

Urges Shareholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY

Visit Vote.Vaxart.com for Additional Information and Voting Resources

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Mon, 01 Jun 2026 08:18:00 -0400

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead

Highlights Significant Risk of Replacing Vaxart’s Highly Qualified Directors with Candidates Who Have No Relevant Expertise

Urges Shareholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY

Visit Vote.Vaxart.com for Additional Information and Voting Resources

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Mon, 01 Jun 2026 08:18:00 -0400

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead

Highlights Significant Risk of Replacing Vaxart’s Highly Qualified Directors with Candidates Who Have No Relevant Expertise

Urges Shareholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY

Visit Vote.Vaxart.com for Additional Information and Voting Resources

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral

Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders

Mon, 01 Jun 2026 08:18:00 -0400

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead

Highlights Significant Risk of Replacing Vaxart’s Highly Qualified Directors with Candidates Who Have No Relevant Expertise

Urges Shareholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY

Visit Vote.Vaxart.com for Additional Information and Voting Resources

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral

Form DEFC14A Vaxart, Inc. Filed by: Vaxart, Inc.

Mon, 01 Jun 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260601/26579718.html

Form DEFC14A Vaxart, Inc. Filed by: Vaxart, Inc.

Mon, 01 Jun 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260601/26579718.html

Form PRER14A Vaxart, Inc.

Fri, 29 May 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260529/26576364.html

Form PRER14A Vaxart, Inc.

Fri, 29 May 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260529/26576364.html

Form PRRN14A Vaxart, Inc. Filed by: Houle Daniel P

Fri, 29 May 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260529/26576111.html

Form PRRN14A Vaxart, Inc. Filed by: Houle Daniel P

Fri, 29 May 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260529/26576111.html

Form 4 Vaxart, Inc. For: May 22 Filed by: Watson W. Mark

Tue, 26 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260526/26551225.html

Form 4 Vaxart, Inc. For: May 22 Filed by: Watson W. Mark

Tue, 26 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260526/26551225.html

Form PREC14A Vaxart, Inc. Filed by: Houle Daniel P

Thu, 21 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260521/26536922.html